- Conditions
- Hepatic Impairment
- Interventions
- Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- Saroglitazar Magnesium 4 mg, Placebo
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 5 more
- Conditions
- Nonalcoholic Steatohepatitis, Fibrosis
- Interventions
- Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, Placebo
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 75 more
- Conditions
- Non Alcoholic Steatohepatitis
- Interventions
- Saroglitazar Magnesium 2mg, Saroglitazar Magnesium 4mg, Placebos
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Jackson, Mississippi • Germantown, Tennessee • Hermitage, Tennessee + 2 more
- Conditions
- Non-alcoholic Fatty Liver Disease in Women With PCOS
- Interventions
- Saroglitazar Magnesium 4 mg Tablet, Placebo
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 13
- States / cities
- Chandler, Arizona • Panorama City, California • San Francisco, California + 9 more
- Conditions
- Liver Transplant; Complications, NAFLD
- Interventions
- Saroglitazar
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebo Oral Tablet
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 9
- States / cities
- Pasadena, California • Miami, Florida • Marietta, Georgia + 5 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Interventions
- Saroglitazar magnesium 1 mg, Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebos
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 18
- States / cities
- Chula Vista, California • Los Angeles, California • Montclair, California + 15 more
- Conditions
- Dyslipidemias
- Interventions
- Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, Placebo
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 33
- States / cities
- Huntsville, Alabama • Encinitas, California • San Diego, California + 29 more